buflomedil has been researched along with Intermittent Claudication in 38 studies
buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A meta-analysis was performed on the results of clinical trials of buflomedil in intermittent claudication." | 10.17 | A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. ( Mac Hannaford, JC; Walker, GA, 1995) |
| " Buflomedil, a vasoactive substance with hemorheological properties, has been widely used in the treatment of intermittent claudication." | 9.09 | Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. ( Diamantopoulos, EJ; Grigoriadou, M; Ifanti, G; Raptis, SA, 2001) |
| "To evaluate the available evidence on the efficacy of buflomedil for intermittent claudication." | 8.81 | Buflomedil for intermittent claudication. ( Bogaert, MG; De Backer, TL; Vander Stichele, RH, 2001) |
| " This issue of bias in benefit-risk assessment of older products is illustrated here with an example: buflomedil in intermittent claudication." | 7.75 | Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. ( De Backer, TL; Van Bortel, LM; Vander Stichele, RH, 2009) |
| "Pentoxifylline was significantly more effective (P < 0." | 6.67 | Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. ( Calleja, F; Casares, J; Chacón-Quevedo, A; Concha, M; Eguaras, MG; Garcia, MA; Muñoz, I; Roman, M, 1994) |
| "Buflomedil is a vasoactive agent widely used in the treatment of peripheral arterial disease." | 6.66 | [Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication]. ( Diehm, C; Eckstein, M; Hübsch-Müller, C, 1989) |
| "Buflomedil is a vasoactive agent used to treat peripheral vascular disease." | 6.49 | Buflomedil for intermittent claudication. ( de Backer, TL; Vander Stichele, R, 2013) |
| "Buflomedil is a vasoactive agent used to treat peripheral vascular disease." | 6.44 | Buflomedil for intermittent claudication. ( Bogaert, M; de Backer, TL; Vander Stichele, R, 2007) |
| "Buflomedil is a vasoactive agent used to treat peripheral vascular disease." | 6.44 | Buflomedil for intermittent claudication. ( Bogaert, M; de Backer, TL; Vander Stichele, R, 2008) |
| " According to our results, buflomedil is more effective and safe than naftidrofuryl in the treatment of patients with intermittent claudication." | 5.26 | Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. ( Cerdeyra, C; Lucas, MA; Parano, JR; Rosas, G; Villa, JJ, 1981) |
| " We performed an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate whether long-term administration of oral buflomedil could reduce the rate of cardiovascular events in patients with intermittent claudication." | 5.13 | Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. ( Becker, F; Leizorovicz, A, 2008) |
| " The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion." | 5.12 | The effects of prostaglandin E-1 in patients with intermittent claudication. ( Coppola, G; Milio, G; Novo, S, 2006) |
| " Buflomedil, a vasoactive substance with hemorheological properties, has been widely used in the treatment of intermittent claudication." | 5.09 | Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. ( Diamantopoulos, EJ; Grigoriadou, M; Ifanti, G; Raptis, SA, 2001) |
| " This issue of bias in benefit-risk assessment of older products is illustrated here with an example: buflomedil in intermittent claudication." | 3.75 | Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. ( De Backer, TL; Van Bortel, LM; Vander Stichele, RH, 2009) |
| "Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated." | 2.45 | Pharmacologic therapy for intermittent claudication. ( Dobesh, PP; Persson, EL; Stacy, ZA, 2009) |
| "Treatment with buflomedil for 3 months led to a significant improvement in signs and symptoms in all four clinical stages." | 1.27 | [Epidemiologic study of peripheral obstructive arteriopathies: clinical effects of treatment with buflomedil chlorhydrate (Loftyl). Processing of data furnished by a polycenter study]. ( , 1985) |
| " According to our results, buflomedil is more effective and safe than naftidrofuryl in the treatment of patients with intermittent claudication." | 1.26 | Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. ( Cerdeyra, C; Lucas, MA; Parano, JR; Rosas, G; Villa, JJ, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (34.21) | 18.7374 |
| 1990's | 10 (26.32) | 18.2507 |
| 2000's | 13 (34.21) | 29.6817 |
| 2010's | 2 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Backer, TL | 7 |
| Vander Stichele, R | 3 |
| Vander Stichele, RH | 4 |
| Van Bortel, LM | 2 |
| Dobesh, PP | 1 |
| Stacy, ZA | 1 |
| Persson, EL | 1 |
| Tryniszewski, W | 1 |
| Nowak, D | 1 |
| Brocki, M | 1 |
| Maziarz, Z | 1 |
| Rysz, J | 1 |
| Landi, A | 1 |
| Neri, C | 1 |
| Barbareschi, M | 1 |
| Turrina, S | 1 |
| De Leo, D | 1 |
| Milio, G | 1 |
| Coppola, G | 1 |
| Novo, S | 1 |
| Bogaert, M | 2 |
| Leizorovicz, A | 1 |
| Becker, F | 1 |
| Conte, MS | 1 |
| Trübestein, G | 2 |
| Balzer, K | 2 |
| Bisler, H | 2 |
| Klüken, N | 2 |
| Muller-Wiefel, H | 2 |
| Unkel, B | 2 |
| Mahfoud, Y | 2 |
| Ziegler, W | 2 |
| Marshall, M | 1 |
| Forconi, S | 1 |
| Pieragalli, D | 1 |
| Acciavatti, A | 1 |
| Del Bigo, C | 1 |
| Galigani, C | 1 |
| Ralli, L | 1 |
| Guerrini, M | 1 |
| Di Perri, T | 1 |
| Dubourg, A | 1 |
| Scamuffa, RF | 1 |
| Rosas, G | 1 |
| Cerdeyra, C | 1 |
| Lucas, MA | 1 |
| Parano, JR | 1 |
| Villa, JJ | 1 |
| Sunder-Plassmann, L | 1 |
| Chacón-Quevedo, A | 1 |
| Eguaras, MG | 1 |
| Calleja, F | 1 |
| Garcia, MA | 1 |
| Roman, M | 1 |
| Casares, J | 1 |
| Muñoz, I | 1 |
| Concha, M | 1 |
| Walker, GA | 1 |
| Mac Hannaford, JC | 1 |
| Van den Brande, P | 1 |
| Maurel, A | 1 |
| Riambau, V | 1 |
| Piñol, C | 1 |
| Pérez Encinas, M | 1 |
| Fernández, MA | 1 |
| Martín, ML | 1 |
| Calvo, MV | 1 |
| Gómez-Alonso, A | 1 |
| Dominguez-Gil, A | 1 |
| Lozano, F | 1 |
| Warie, HH | 1 |
| Bogaert, MG | 2 |
| Diamantopoulos, EJ | 1 |
| Grigoriadou, M | 1 |
| Ifanti, G | 1 |
| Raptis, SA | 1 |
| Weiss, T | 1 |
| Fujita, Y | 1 |
| Kreimeier, U | 1 |
| Messmer, K | 1 |
| Diehm, C | 2 |
| Ehrly, AM | 1 |
| Saeger-Lorenz, K | 1 |
| Andreozzi, GM | 1 |
| Lepore, R | 1 |
| Scheffler, A | 1 |
| Rieger, H | 1 |
| Eckstein, M | 1 |
| Hübsch-Müller, C | 1 |
| Visconti, W | 1 |
| Grillo, N | 1 |
| Fonseca, V | 1 |
| Mikhailidis, DP | 1 |
| Barradas, MA | 1 |
| Jeremy, JY | 1 |
| Gracey, L | 1 |
| Dandona, P | 1 |
| Heidrich, H | 1 |
| Dorigo, B | 1 |
| Raspanti, D | 1 |
| Trapani, M | 1 |
| Albanese, B | 1 |
| Cameli, AM | 1 |
| Digiesi, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF[NCT00765050] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2009-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for buflomedil and Intermittent Claudication
| Article | Year |
|---|---|
Buflomedil for intermittent claudication.
Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr | 2013 |
Pharmacologic therapy for intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Dietary Supplements; Drugs, Investigational; Exercise Therapy; | 2009 |
[Secondary prevention and conservative therapy of obliterative arteriosclerosis].
Topics: Arteriosclerosis Obliterans; Cilostazol; Clinical Trials as Topic; Epoprostenol; Exercise; Hematolog | 2004 |
Buflomedil for intermittent claudication.
Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr | 2007 |
Buflomedil for intermittent claudication.
Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr | 2008 |
An experimental overview of a new vasoactive drug: buflomedil HCl.
Topics: Animals; Cerebrovascular Disorders; Chronic Disease; Coronary Disease; Dogs; Hemodynamics; Humans; I | 1981 |
A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
Topics: Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudication; Male; Multicenter Stu | 1995 |
[Intermittent claudication: review of a disease of growing prevalence. II. Treatment].
Topics: Adrenergic alpha-Antagonists; Algorithms; Blood Vessel Prosthesis Implantation; Clinical Trials as T | 1998 |
Oral vasoactive medication in intermittent claudication: utile or futile?
Topics: Administration, Oral; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Pyrrolidines; Ran | 2000 |
Buflomedil for intermittent claudication.
Topics: Administration, Oral; Double-Blind Method; Humans; Intermittent Claudication; Publication Bias; Pyrr | 2001 |
14 trials available for buflomedil and Intermittent Claudication
| Article | Year |
|---|---|
Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Disease Progr | 2008 |
The effects of prostaglandin E-1 in patients with intermittent claudication.
Topics: Adult; Aged; Alprostadil; Drug Combinations; Exercise Test; Female; Humans; Infusions, Intravenous; | 2006 |
Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Disease Progr | 2008 |
Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
Topics: Aged; Arterial Occlusive Diseases; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Hu | 1984 |
[Buflomedil in arterial occlusive disease. Results of a controlled study].
Topics: Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Femoral Ar | 1982 |
Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Exercise Test; Humans; Intermittent Claudication; | 1994 |
A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
Topics: Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudication; Male; Multicenter Stu | 1995 |
A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Chronic Disease; Dose-Response Relationship, D | 1998 |
Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Erythrocyte Deformability; Female; Hemorheology; Hum | 2001 |
[Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Delayed-Action Preparations | 1990 |
[Acral skin circulation following intra-arterial infusion of vasodilating substances in patients with intermittent claudication].
Topics: Aged; Alprostadil; Fluorescein Angiography; Foot; Humans; Intermittent Claudication; Male; Middle Ag | 1990 |
[Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication].
Topics: Clinical Trials as Topic; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Intermi | 1989 |
Double-blind placebo-controlled trial of buflomedil in intermittent claudication.
Topics: Aged; Blood Pressure; Double-Blind Method; Female; Humans; Intermittent Claudication; Male; Middle A | 1988 |
[Vasoactive drugs in peripheral arterial perfusion disorders. Problems, principles and results of the determination of therapeutic efficacy].
Topics: Arterial Occlusive Diseases; Cardiovascular Agents; Cinnarizine; Clinical Trials as Topic; Dihydroer | 1985 |
15 other studies available for buflomedil and Intermittent Claudication
| Article | Year |
|---|---|
Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.
Topics: Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Adverse R | 2009 |
Influence of pharmacological treatment on blood flow and muscle perfusion in patients with obliterative atheromatosis assessed with isotopic methods. A pilot study.
Topics: Analysis of Variance; Arteriosclerosis Obliterans; Aspirin; Blood Flow Velocity; Exercise; Female; H | 2010 |
Suicide by buflomedil HCl: a case report.
Topics: Drug Overdose; Gas Chromatography-Mass Spectrometry; Humans; Intermittent Claudication; Male; Middle | 2004 |
Buflomedil in peripheral arterial disease: trials and tribulations.
Topics: Adrenergic alpha-Antagonists; Cardiovascular Diseases; Disease Progression; Humans; Intermittent Cla | 2008 |
[Arterio-vascular diseases. New trends in diagnosis and therapy].
Topics: Arterial Occlusive Diseases; Humans; Intermittent Claudication; Pyrrolidines; Vasodilator Agents | 1983 |
Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
Topics: Administration, Oral; Arterial Occlusive Diseases; Blood Viscosity; Female; Humans; Hydrogen-Ion Con | 1984 |
Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
Topics: Butyrophenones; Double-Blind Method; Evaluation Studies as Topic; Furans; Humans; Intermittent Claud | 1981 |
[Improved microcirculation and collateral circulation in arterial occlusive diseases of the lower extremity].
Topics: Animals; Arterial Occlusive Diseases; Collateral Circulation; Dogs; Hemodilution; Hindlimb; Intermit | 1981 |
Multicriteria decision analysis for determining drug therapy for intermittent claudication.
Topics: Decision Support Techniques; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Probabilit | 1998 |
Effect of intensive walking exercise on skeletal muscle blood flow in intermittent claudication.
Topics: Administration, Oral; Animals; Combined Modality Therapy; Dogs; Drug Evaluation, Preclinical; Exerci | 1992 |
[Possibilities and limits of physical training therapy of intermittent claudication patients with simultaneous drug therapy].
Topics: Alprostadil; Combined Modality Therapy; Exercise; Follow-Up Studies; Humans; Intermittent Claudicati | 1991 |
Exercise-induced variations in muscle tissue oxygen pressure in claudicants: effects of buflomedil.
Topics: Adult; Aged; Exercise; Humans; Intermittent Claudication; Middle Aged; Muscles; Oxygen Consumption; | 1991 |
[Buflomedil in the treatment of chronic peripheral arterial diseases. Case contribution].
Topics: Aged; Arterial Occlusive Diseases; Drug Tolerance; Female; Humans; Intermittent Claudication; Male; | 1985 |
[Flowmetric, thermometric and rheologic studies in obliterating arterial diseases of the lower extremities treated with buflomedil].
Topics: Aged; Arterial Occlusive Diseases; Blood Flow Velocity; Blood Viscosity; Drug Administration Schedul | 1985 |
[Epidemiologic study of peripheral obstructive arteriopathies: clinical effects of treatment with buflomedil chlorhydrate (Loftyl). Processing of data furnished by a polycenter study].
Topics: Administration, Oral; Age Factors; Aged; Arterial Occlusive Diseases; Female; Humans; Infusions, Par | 1985 |